Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study
E. Fountzilas , S. Karageorgopoulou , G. Karakatsoulis , D. Tryfonopoulos , K. Papazisis , A. Koutras , A. Koumarianou , G. Zafeiri , E. Biziota , A. Nikolaidi , I. Boukovinas , E. Vrana , D. Mauri , E. Aravantinou-Fatorou , E. Razis , E. Vorrias , Z. Saridaki , D. Bafaloukos , A. Christopoulou , A. Boutis , E. Lalla
{"title":"Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study","authors":"E. Fountzilas , S. Karageorgopoulou , G. Karakatsoulis , D. Tryfonopoulos , K. Papazisis , A. Koutras , A. Koumarianou , G. Zafeiri , E. Biziota , A. Nikolaidi , I. Boukovinas , E. Vrana , D. Mauri , E. Aravantinou-Fatorou , E. Razis , E. Vorrias , Z. Saridaki , D. Bafaloukos , A. Christopoulou , A. Boutis , E. Lalla","doi":"10.1016/j.esmorw.2024.100095","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The study aimed to evaluate real-world effectiveness and toxicity data of trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in pretreated patients with metastatic breast cancer (mBC).</div></div><div><h3>Patients and methods</h3><div>A retrospective multicenter review of medical records of patients with mBC treated with T-DXd and/or SG at 24 Departments of Oncology, affiliated with the Hellenic Cooperative Oncology Group (HeCOG) was carried out. Patients with triple-negative BC (TNBC), HER2-positive, and/or hormone receptor (HR)-positive mBC who received at least one cycle of T-DXd and/or SG in any line of treatment were included. The primary endpoint was the toxicity rate of each drug.</div></div><div><h3>Results</h3><div>From January 2020 to April 2024, 312 patients received treatment; 226 (72.4%) received T-DXd and 60 (19.2%) SG, while 26 (8.3%) patients received both agents. Adverse events (AEs) were reported in 57.1% of patients treated with T-DXd and 56.6% of patients treated with SG. The most common AEs were nausea (28.1%) and fatigue (22.5%) among patients treated with T-DXd, and fatigue (20.7%) and neutropenia (12.6%) among those treated with SG. Toxicity-related discontinuation was reported in 12 (8.8%) and 2 (3.2%) patients, respectively, who received T-DXd and SG. Interstitial lung disease was observed in 17 (6.9%) patients treated with T-DXd. The 12-month progression-free survival (PFS) rate was 69.6 [interquartile range (IQR) 61.4-79] in patients with HER2-positive and 46.5 (IQR 28.6-46.5) in patients with HER2-low mBC receiving T-DXd. In patients with TNBC receiving SG, the 12-month PFS rate was 16.2 (IQR 8.1-32.4), whereas in patients with HR-positive/HER2-negative mBC, it was 23.6 (IQR 13.8-40.3).</div></div><div><h3>Conclusions</h3><div>Real-world data on the use of T-DXd and SG in patients with mBC provide significant clinical insights into the toxicity and effectiveness of each agent.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"7 ","pages":"Article 100095"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Real World Data and Digital Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949820124000730","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background
The study aimed to evaluate real-world effectiveness and toxicity data of trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in pretreated patients with metastatic breast cancer (mBC).
Patients and methods
A retrospective multicenter review of medical records of patients with mBC treated with T-DXd and/or SG at 24 Departments of Oncology, affiliated with the Hellenic Cooperative Oncology Group (HeCOG) was carried out. Patients with triple-negative BC (TNBC), HER2-positive, and/or hormone receptor (HR)-positive mBC who received at least one cycle of T-DXd and/or SG in any line of treatment were included. The primary endpoint was the toxicity rate of each drug.
Results
From January 2020 to April 2024, 312 patients received treatment; 226 (72.4%) received T-DXd and 60 (19.2%) SG, while 26 (8.3%) patients received both agents. Adverse events (AEs) were reported in 57.1% of patients treated with T-DXd and 56.6% of patients treated with SG. The most common AEs were nausea (28.1%) and fatigue (22.5%) among patients treated with T-DXd, and fatigue (20.7%) and neutropenia (12.6%) among those treated with SG. Toxicity-related discontinuation was reported in 12 (8.8%) and 2 (3.2%) patients, respectively, who received T-DXd and SG. Interstitial lung disease was observed in 17 (6.9%) patients treated with T-DXd. The 12-month progression-free survival (PFS) rate was 69.6 [interquartile range (IQR) 61.4-79] in patients with HER2-positive and 46.5 (IQR 28.6-46.5) in patients with HER2-low mBC receiving T-DXd. In patients with TNBC receiving SG, the 12-month PFS rate was 16.2 (IQR 8.1-32.4), whereas in patients with HR-positive/HER2-negative mBC, it was 23.6 (IQR 13.8-40.3).
Conclusions
Real-world data on the use of T-DXd and SG in patients with mBC provide significant clinical insights into the toxicity and effectiveness of each agent.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
